Abstract
We have investigated whether one or two pharmacophores are required for the kappa opioid receptor selectivity of the bivalent opioid antagonist norbinaltorphimine, (-)-1 (nor-BNI), by the synthesis and testing of its meso isomer 2. In smooth muscle preparations 2 was more potent than 1 and about half as selective as a kappa antagonist. Since 2 contains only one antagonist pharmacophore but yet retains substantial kappa selectivity, it is concluded that kappa selectivity is not dependent on the presence of two (-)-naltrexone-derived pharmacophores of 1. It is suggested that the kappa selectivity of (-)-1 and 2 is derived from the portions of the second halves of these molecules in that they mimic key "address" components of dynorphin at kappa opioid receptors.
Publication types
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Chemical Phenomena
-
Chemistry
-
Cyclazocine / analogs & derivatives
-
Cyclazocine / antagonists & inhibitors
-
Enkephalin, Leucine / analogs & derivatives
-
Enkephalin, Leucine / antagonists & inhibitors
-
Enkephalin, Leucine-2-Alanine
-
Ethylketocyclazocine
-
Guinea Pigs
-
Ileum / drug effects
-
Ileum / physiology
-
Male
-
Mice
-
Morphine / antagonists & inhibitors
-
Naltrexone / analogs & derivatives*
-
Naltrexone / pharmacology
-
Receptors, Opioid / drug effects*
-
Receptors, Opioid / physiology
-
Receptors, Opioid, kappa
-
Stereoisomerism
-
Structure-Activity Relationship
-
Vas Deferens / drug effects
-
Vas Deferens / physiology
Substances
-
Receptors, Opioid
-
Receptors, Opioid, kappa
-
norbinaltorphimine
-
Ethylketocyclazocine
-
Enkephalin, Leucine
-
Naltrexone
-
Enkephalin, Leucine-2-Alanine
-
Morphine
-
Cyclazocine